Lupin intros Kerydin generic
Branded and generic versions of the product had U.S. sales of $53 million for the year ended May 2021, according to IQVIA data.
Lupin is rolling out its generic Kerydin (tacaborole topical solution, 5%). The antifungal was previously approved by the Food and Drug Administration.
The generic is indicated for the topical treatment of onychomycosis of the toenails caused by trichophyton rubrum or trichophyton mentagrophytes.
Branded and generic versions of the product had U.S. sales of $53 million for the year ended May 2021, according to IQVIA data.